Literature DB >> 1386852

Cyclin A-cdc2 kinase does not trigger but delays cyclin degradation in interphase extracts of amphibian eggs.

T Lorca1, J C Labbé, A Devault, D Fesquet, U Strausfeld, J Nilsson, P A Nygren, M Uhlen, J C Cavadore, M Dorée.   

Abstract

Purified cyclin B-cdc2 kinase has been shown previously to trigger cyclin degradation in interphase frog extracts by initiating a cascade of reactions that includes cyclin ubiquitinylation and ends with proteolysis. However, cyclin A-cdc2 kinase was not assayed in these early experiments. Here we have shown that full-length recombinant human cyclin A failed to induce cyclin degradation when it was added to frog extracts free of cyclin B, although it formed an active kinase complex with Xenopus cdc2. A highly purified kinase complex containing a truncated human cyclin A and starfish cdc2 also failed to switch on the cyclin degradation pathway. In contrast, both recombinant cyclin B and highly purified cyclin B-cdc2 kinase readily triggered degradation of both cyclins B and A in frog extracts. Whilst free cyclin A had no inhibitory effect, cyclin A-cdc2 kinase delayed degradation of both cyclins A and B induced by cyclin B-cdc2 kinase. The finding that cyclin A-cdc2 kinase cannot turn on, and even delays, cyclin destruction may be essential to prevent premature inactivation of MPF (maturation-promoting factor) before complete condensation of chromosomes and formation of the metaphase spindle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386852     DOI: 10.1242/jcs.102.1.55

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  16 in total

1.  A nuclear factor required for specific translation of cyclin B may control the timing of first meiotic cleavage in starfish oocytes.

Authors:  S Galas; H Barakat; M Dorée; A Picard
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

2.  MAPK inactivation is required for the G2 to M-phase transition of the first mitotic cell cycle.

Authors:  A Abrieu; D Fisher; M N Simon; M Dorée; A Picard
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

3.  Mitogen-activated protein kinase activation down-regulates a mechanism that inactivates cyclin B-cdc2 kinase in G2-arrested oocytes.

Authors:  A Abrieu; M Dorée; A Picard
Journal:  Mol Biol Cell       Date:  1997-02       Impact factor: 4.138

Review 4.  Cyclins and cyclin-dependent kinases: a biochemical view.

Authors:  J Pines
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

5.  The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis.

Authors:  V Sudakin; D Ganoth; A Dahan; H Heller; J Hershko; F C Luca; J V Ruderman; A Hershko
Journal:  Mol Biol Cell       Date:  1995-02       Impact factor: 4.138

6.  In vitro fusion of endocytic vesicles is inhibited by cyclin A-cdc2 kinase.

Authors:  P G Woodman; J P Adamczewski; T Hunt; G Warren
Journal:  Mol Biol Cell       Date:  1993-05       Impact factor: 4.138

7.  Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor.

Authors:  Tsz Kan Fung; Hoi Tang Ma; Randy Y C Poon
Journal:  Mol Biol Cell       Date:  2007-03-07       Impact factor: 4.138

8.  The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues.

Authors:  D Fesquet; J C Labbé; J Derancourt; J P Capony; S Galas; F Girard; T Lorca; J Shuttleworth; M Dorée; J C Cavadore
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

9.  Human cyclin F.

Authors:  C Bai; R Richman; S J Elledge
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

10.  p40MO15 associates with a p36 subunit and requires both nuclear translocation and Thr176 phosphorylation to generate cdk-activating kinase activity in Xenopus oocytes.

Authors:  J C Labbé; A M Martinez; D Fesquet; J P Capony; J M Darbon; J Derancourt; A Devault; N Morin; J C Cavadore; M Dorée
Journal:  EMBO J       Date:  1994-11-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.